Linaprazan

Linaprazan is an experimental drug for the treatment of gastroesophageal reflux disease. Unlike the proton-pump inhibitors which are typically used to treat GERD, linaprazan is a potassium-competitive acid blocker. Linaprazan was developed by AstraZeneca, but it was not successful in clinical trials.
The drug was then licensed to Cinclus Pharma, which is now investigating linaprazan glurate, a prodrug of linaprazan which is expected to have a longer biological half-life than linaprazan itself.